Plunkett Research Online: Eiger BioPharmaceuticals

EIGER BIOPHARMACEUTICALS (EIGR:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Eiger BioPharmaceuticals Inc is a clinical stage biopharmaceutical company. It is focused on bringing to market novel product candidates for the treatment of orphan diseases. The company's lead program is Lonafarnib, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infec.....



Eiger BioPharmaceuticals
Ticker: EIGR
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 650 272-6138
Fax: 650 618-1621
Address: 2155 Park Boulevard
Palo Alto, CA 94306 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Vaccines, Skin Replacement Products and Biologicals Manufacturing
ContactsDescription

David CoryCEO/Director/President
Sriram RyaliCFO/Chief Accounting Officer
See More
Eiger BioPharmaceuticals Inc is a clinical stage biopharmaceutical company. It is focused on bringing to market novel product candidates for the treatment of orphan diseases. The company's lead program is Lonafarnib, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infec.....See More See More

Auditor: KPMG LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201820172016201520142013
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: